Wegovy and Ozempic Linked to Vision Loss: What You Demand to Know

Recent research suggests a potential link between semaglutide, the active ingredient in weight-loss drugs Wegovy and Ozempic, and an increased risk of vision loss. A study published in the British Journal of Ophthalmology analyzed data from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System and found a higher incidence of ischemic optic neuropathy (ION), often called an “eye stroke,” among users of these medications.

What is Ischemic Optic Neuropathy?

Ischemic optic neuropathy (ION) occurs when blood flow to the optic nerve is disrupted, leading to sudden vision loss. The American Academy of Ophthalmology describes ION as a serious condition that can cause permanent vision impairment.

Study Findings: Wegovy, Ozempic, and Rybelsus

Researchers examined over 31,774 reports involving semaglutide submitted to the FDA between December 2017 and December 2024. The analysis revealed:

• 3,070 reports were attributed to Wegovy, which was launched in 2021.
• 20,608 reports were linked to Ozempic, approved by the FDA in 2017.
• Despite Ozempic having more total reports due to its earlier approval, Wegovy showed a stronger association with ION.
• The odds of ION were almost five times higher with Wegovy compared to Ozempic.
• Men were more than three times more likely to experience ION than women.
• No ION reports were associated with Rybelsus, another semaglutide medication, potentially due to its different absorption rate.

Dose-Dependent Risk

The study suggests a “dose-dependent safety concern,” meaning the risk of ION appears to increase with higher doses of semaglutide. Wegovy utilizes a higher dose of semaglutide for weight management, while Ozempic and Rybelsus employ lower doses for treating type 2 diabetes.

Novo Nordisk’s Response

Novo Nordisk, the manufacturer of Wegovy, Ozempic, and Rybelsus, stated that patient safety is their top priority and they are closely monitoring the safety profiles of their products. The company has updated EU patient leaflets to include information about non-arteritic anterior ischemic optic neuropathy (NAION). Although, Novo Nordisk maintains that data does not establish a causal relationship between semaglutide and NAION, and believes the benefit-risk profile of semaglutide remains favorable.

What Does This Mean for Patients?

Researchers emphasize the need for urgent prospective evaluation to guide prescribing practices and regulatory policy. Individuals taking Wegovy or Ozempic should be aware of the potential risk of ION and report any sudden vision changes to their healthcare provider immediately.

Key Takeaways

• Wegovy is associated with a higher risk of ION compared to Ozempic.
• Men may be at a greater risk of developing ION while taking these medications.
• The risk appears to be dose-dependent.
• Patients should report any sudden vision changes to their doctor.